Alopecia: Absence of hair from areas where it is normally present.
Notice: A non well formed numeric value encountered in /home/lookformedical/www/definitions.php on line 64
Globosides: Glycosphingolipids containing N-acetylglucosamine (paragloboside) or N-acetylgalactosamine (globoside). Globoside is the P antigen on erythrocytes and paragloboside is an intermediate in the biosynthesis of erythrocyte blood group ABH and P 1 glycosphingolipid antigens. The accumulation of globoside in tissue, due to a defect in hexosaminidases A and B, is the cause of Sandhoff disease.Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).Hair Follicle: A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.Hair: A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)Scalp DermatosesFolliculitis: Inflammation of follicles, primarily hair follicles.Dermoscopy: A noninvasive technique that enables direct microscopic examination of the surface and architecture of the SKIN.Tinea Capitis: Ringworm of the scalp and associated hair mainly caused by species of MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON, which may occasionally involve the eyebrows and eyelashes.Trichotillomania: Compulsion to pull out one's hair.Cicatrix: The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.Photophobia: Abnormal sensitivity to light. This may occur as a manifestation of EYE DISEASES; MIGRAINE; SUBARACHNOID HEMORRHAGE; MENINGITIS; and other disorders. Photophobia may also occur in association with DEPRESSION and other MENTAL DISORDERS.Lichen Planus: An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a "saw-tooth" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.Eyebrows: Curved rows of HAIR located on the upper edges of the eye sockets.Triethylenephosphoramide: An insect chemosterilant and an antineoplastic agent.Hypotrichosis: Presence of less than the normal amount of hair. (Dorland, 27th ed)Skin: The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.Ichthyosis: Any of several generalized skin disorders characterized by dryness, roughness, and scaliness, due to hypertrophy of the stratum corneum epidermis. Most are genetic, but some are acquired, developing in association with other systemic disease or genetic syndrome.Sebaceous Glands: Small, sacculated organs found within the DERMIS. Each gland has a single duct that emerges from a cluster of oval alveoli. Each alveolus consists of a transparent BASEMENT MEMBRANE enclosing epithelial cells. The ducts from most sebaceous glands open into a HAIR FOLLICLE, but some open on the general surface of the SKIN. Sebaceous glands secrete SEBUM.

*  Geometry.Net - Health Conditions: Baldness
Color Mutant Alopecia, Congenital Alopecia, etc. The term Color Mutant Alopecia arose because dilutes were at one time ... Hair, Baldness, Hair Loss Disease, Alopecia, Hirsutism, And Hypertrichosis Infor, hair loss, baldness, alopecia, ... Color Dilution Alopecia By Teri Dickinson, DVM Alopecia (hair loss) related to dilute coat color is a recognized condition in ... Extractions: Color Dilution Alopecia By Teri Dickinson, DVM Alopecia (hair loss) related to dilute coat color is a recognized ...
*  causes of alopecia | The Griffin Center of Hair Restoration & Research
Alopecia areata is another type of hair loss that may be confused with scarring alopecia. In most cases, alopecia areata ... The Many Faces of Alopecia Alopecia is the partial or complete loss of hair from areas of the body where it normally grows. ... Finally cicatricial alopecia (also known as scarring alopecia) results from the destruction of hair follicles caused by the ... In general, scarring alopecia (cicatricial alopecia) can occur in healthy individuals and can potentially cause permanent and ...
*  Experts Identify Inhibitor Causing Male Pattern Baldness And Target For Hair-Loss Treatments - Redorbit
... which is a promising therapeutic target for androgenetic alopecia in both men and women with hair loss and thinning. ... bald scalp tissue at levels 3 times greater than what was found in comparative haired scalp of men with androgenetic alopecia. ...
*  Androgenetic Alopecia in Fabry Disease - Full Text View -
Alopecia. Alopecia Areata. Hypotrichosis. Sphingolipidoses. Metabolism, Inborn Errors. Lipidoses. Lipid Metabolism, Inborn ... No and frontal only androgenetic alopecia [ Time Frame: 1 Year ]. No and frontal only androgenetic alopecia opposed to vertex ... Outcome Measures: The levels of the outcome will be no androgenic alopecia and frontal only androgenetic alopecia opposed to ... Vertex only and frontal and vertex androgenetic alopecia. [ Time Frame: 1 Year ]. No and frontal only androgenetic alopecia ...
*  Alopecia, Androgenetic Alopecia Treatment Alternative Medicine, Alopecia Alternative Treatment, Alopecia Neuro Acupuncture...
Androgenetic Alopecia Treatment of Alternative Alopecia Medicine Treatment, Alternative Androgenetic Alopecia Medicine ... Treatment on Alopecia Treatment Medical Center Alopecia Remedies ... What is Alopecia ? Medically hair loss is alopecia, Pattern ... the most common type of alopecia. It's typically permanent. Another type of alopecia, alopecia areata, can be temporary. It can ... Alopecia Alternative Herbs Medicine Treatment, Alopecia Alternative Treatment Medical Centre, Androgenetic Alopecia Remedies ...
*  Faq & Common Terms - The Stough Clinic
Alopecia totalis - Hair loss affecting the entire scalp. Alopecia universalis - Hair loss on entire body. Hair follicles ... Many sub categories of alopecia exist.. Alopecia areata - Hair loss disorder characterized by patchy smooth areas of hair loss ... Traction alopecia - Hair loss due to tension on scalp from tight braids, ponytails, hair extensions, etc. ... Androgenetic alopecia - Hair loss related to gender. Usually occurs in a specific pattern ...
*  Male Pattern Hair Loss (Androgenetic Alopecia) | About Dermatology
Learn about what causes androgenetic alopecia and available treatments. ... Male Pattern Hair Loss (Androgenetic Alopecia). 18 Mar, 2016. in Common Conditions tagged androgenetic alopecia / avodart / ... Platelet Rich Plasma for Alopecia. PRP is exactly what it says in the name. Your blood is made up of cells and plasma. One type ... One thought on "Male Pattern Hair Loss (Androgenetic Alopecia)". * Pingback: Supplements for Hair Growth: Do they work? , About ...
*  androgenic alopecia Hair Loss Tips
Another signal that you have androgenic alopecia is the size of the hair you may be losing. Normally hair grows at about six ... If you believe you have androgenic alopecia then there are procedures you are able to take to stop your hair reduction and re- ... MPB is the man variation of the type of hair reduction well-known as androgenic alopecia. It has been determined that ... Both these conditions are termed as androgenic alopecia. How have you figured out should you have this condition? Here are some ...
*  Types of Hair Loss - Alopecia
Alopecia Totalis, Alopecia Universalis, Alopecia Barbae, Androgenetic Alopecia, Scarring Alopecias, Traction Alopecia, Anagen ... Cicatricial Alopecia. Cicatricial Alopecia, also known as Scarring Alopecia, is caused by the destruction of the hair follicle ... Traction Alopecia. Traction Alopecia is defined as hair loss resulting from either prolonged or repetitive pulling force to the ... Ocasionally, Alopecia Areata may progress to complete baldness, which is refferd to as Alopecia Totalis, and when the entire ...
*  androgenic alopecia Archives - More Plates More Dates
You are here: Home / Archives for androgenic alopecia. The Best Hair Loss Prevention Shampoo. October 7, 2017. By Derek 6 ... Filed Under: Hair Loss Prevention Tagged With: aarc, anagen, androgenic alopecia, anti-androgen, anti-dht, DHT, hair growth, ... Filed Under: Hair Loss Prevention, Look Good Tagged With: aarc, anabolics, Anageninc, androgenic alopecia, best hair loss ... Filed Under: Bodybuilding, Hair Loss Prevention Tagged With: androgenic alopecia, anti-androgen, anti-dht, Deca, dutasteride, ...
*  Male pattern baldness or Androgenic Alopecia :: Male pattern baldness or Androgenic Alopecia
It is also known as androgenic alopecia because it is related to androgen hormones. ... Diffuse Patterned Alopecia (DPA) is also an androgenetic alopecia characterized by diffuse thinning in the front, top, and ... Alopecia Treatment Center 1/3839 Nani Desai Pole, Nr. Maltiben's Hospital, Soni Falia, Surat - 395003. (Gujarat) India.. Phone ... Diffuse Unpatterned Alopecia (DUPA) is also androgenetic, but lacks a stable permanent zone. DPA patients are often good ...
*  Causes For Hair Loss Problem in Women
2. ALOPECIA AREATA:. Alopecia areata is an immune disease that affects almost 1% of the population. This type of hair loss ... ANDROGENETIC ALOPECIA:. This is an inherited pattern of hair loss and it is the most common cause of permanent hair loss in ... 3.TRACTIONAL ALOPECIA:. This condition is caused by local injury to the hair follicles from tight hair styles that pull at hair ... Androgenetic alopecia in men is what is known as male pattern baldness -hair loss that starts at the front of the scalp and ...
*  Posts by Princess | Medication Information Center
This entry was posted in Finasteride 1mg and tagged 5-alpha reductase inhibitor, androgenic alopecia, finasteride 1mg on ... Finasteride 1mg is the only medication approved by the FDA used for the treatment of androgenic alopecia or male pattern ... hand is very much capable and very helpful in solving the hormone factor issue to totally stop and prevent androgenic alopecia ...
*  Hair Transplantation Technique and peri operative course in the hospital | Room Therapy
Male pattern baldness or Androgenic alopecia is a common problem where the patients are misled by improper marketing by ...
*  Baldness news - One best Rare Male Pattern Baldness Cure Exposed | 1 Top FitnesS
There may be very good news for men and bald women waiting for a ' miracle cure baldness news. ' New research has revealed a discovery of a specific protein that is required in the formation and growth of new hair follicles baldness cure news in particularly in the human body .In other words, the…
*  Forms of Hair Loss | Male Pattern Baldness | Houston, TX Apollo Image Enhancement Center
Different Types of Alopecia. Totalis: This form of alopecia takes its toll on the entire scalp. ... Androgenic Alopecia (also known as "male pattern hair loss") is the cause of more than 95% of thinning in men. This form of ...
*  Androgenetic Alopecia
... is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined ... Androgenetic alopecia is the most common type of hair loss, affecting women (50% of menopausal women and a large number of ... Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most ... Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a ...
*  Visual Impromptu Hair Replacements for Men's and Women's Hair Loss from Alopecia Areata, male pattern baldness, female hair...
Visual Impromptu Hair Replacements for Men's and Women's Hair Loss from Alopecia Areata, male pattern baldness, female hair ...
*  Alopecia areata - Wikipedia
a b c d e f g h i Zoe Diana Draelos (August 30, 2007), Alopecia Areata Archived 2007-12-08 at the Wayback Machine.. MedicineNet ... Trichotillomania, alopecia mucinosa, postpartum alopecia[1]. Treatment. Sunscreen, head coverings to protect from sun and cold[ ... Alopecia areata and alopecia barbae have been identified by some as the biblical nethek condition that is part of the greater ... a b c d e f Alopecia Areata at Merck Manual of Diagnosis and Therapy Professional Edition ...
*  Alopecia mucinosa - Wikipedia
Alopecia mucinosa (also known as "Follicular mucinosis," "Mucinosis follicularis,",[1] "Pinkus' follicular mucinosis,"[1] and " ... Retrieved from "" ...
*  Alopecia: Kayla's Story
Finally, when I was almost 12, I was diagnosed with alopecia areata. Doctors believe alopecia areata is an autoimmune disease ... alopecia areata.'. Her classmates needed no explanation since it was obvious that the girl had lost her eyelashes, eyebrows, ...
*  Alopecias | SpringerLink
Hair Follicle Sebaceous Gland Lichen Planus Mycosis Fungoides Alopecia Areata These keywords were added by machine and not by ... Smoller B.R., Hiatt K.M. (2010) Alopecias. In: Inflammatory Dermatoses: The Basics. Springer, Boston, MA. * DOI ...
*  Patterned alopecia definition |
Definition of patterned alopecia. Provided by Stedman's medical dictionary and Includes medical terms and ...
*  Alopecia leprotica definition |
Definition of alopecia leprotica. Provided by Stedman's medical dictionary and Includes medical terms and ... alopecia leprotica. Definition: thinning or total loss of the lateral third of the eyebrows, eyelashes, and body hairs, seen in ...
ALOPECIA AREATA AND STRABISMUS. Br Med J 1922; 2 doi: (Published 18 November 1922) ...

Central centrifugal cicatricial alopecia: Central centrifugal cicatricial alopecia (CCCA), also referred to as hot comb alopecia and follicular degeneration syndrome, is a type of alopecia first noticed in African Americans in the 1950s and reported by LoPresti et al. in 1968 as a result of application of petrolatum followed by a stove-heated iron comb.
Notice: A non well formed numeric value encountered in /home/lookformedical/www/wikipedia.php on line 80
Lactotriaosylceramide beta-1,4-galactosyltransferase: Lactotriaosylceramide beta-1,4-galactosyltransferase (, beta4Gal-T4, UDP-galactose:N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide beta-1,4-galactosyltransferase) is an enzyme with system name UDP-alpha-D-galactose:N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide 4-beta-D-galactosyltransferase. This enzyme catalyses the following chemical reactionScalp reconstruction: Scalp reconstruction is a surgical procedure for people with scalp defects. Scalp defects may be partial or full thickness and can be congenital or acquired.Hair follicle nevus: Hair follicle nevus (also known as a "Vellus hamartoma") is a cutaneous condition that presents as a small papule from which fine hairs protrude evenly from the surface.Hair analysisMinoxidilBeare–Stevenson cutis gyrata syndrome: Beare–Stevenson cutis gyrata syndrome is a rare genetic disorder characterized by craniosynostosis (premature fusion of certain bones of the skull, sometimes resulting in a characteristic 'cloverleaf skull'; further growth of the skull is prevented, and therefore the shape of the head and face is abnormal) and a specific skin abnormality, called cutis gyrata, characterized by a furrowed and wrinkled appearance (particularly in the face and on the palms and soles of the feet); thick, dark, velvety areas of skin (acanthosis nigricans) are sometimes found on the hands and feet and in the groin.http://ghr.Eosinophilic pustular folliculitis of infancy: Eosinophilic pustular folliculitis of infancy (also known as "Eosinophilic pustular folliculitis in infancy," "Infantile eosinophilic pustular folliculitis," and "Neonatal eosinophilic pustular folliculitis") is a cutaneous condition characterized by recurrent pruritic crops of follicular vesiculopustular lesions.Antonella Tosti: Antonella Tosti is an Italian physician and scientist with major contributions in the field of dermatology.Tinea capitis: (ILDS B35.006) |TrichotillomaniaIchthyosis follicularis with alopecia and photophobia syndromeGraham-Little syndrome: Graham-Little syndrome is a cutaneous condition characterized by lichen planus-like skin lesions.Freedberg, et al.Eyebrow: The eyebrow is an area of thick, delicate hairs above the eye that follows the shape of the lower margin of the brow ridges of some mammals. Their main function is hypothesized to prevent sweat, water, and other debris from falling down into the eye socket, but they are also important to human communication and facial expression.Marie Unna hereditary hypotrichosis: Marie Unna hereditary hypotrichosis (also known as "Marie Unna hypotrichosis") is an autosomal dominant condition characterized by scalp hair that is sparse or absent at birth, with variable coarse, wiry hair regrowth in childhood, and potential loss again at puberty.Freedberg, et al.Dermal equivalent: The dermal equivalent is an in vitro model of the dermal layer of skin. It is constructed by seeding dermal fibroblasts into a collagen gel.Ichthyosis

(1/646) Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.

PURPOSE: Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent cancer of the cervix, and the combination of these two agents has shown activity and possible synergism in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent cervical cancer to evaluate its activity. PATIENTS AND METHODS: Thirty-four consecutive patients were treated on an outpatient basis with paclitaxel 175 mg/m2 administered intravenously over a 3-hour period followed by cisplatin 75 mg/m2 administered intravenously with granulocyte colony-stimulating factor support. The chemotherapy was administered every 3 weeks for a maximum of six courses. RESULTS: Sixteen patients (47%; 95% confidence interval, 30% to 65%) achieved an objective response, including five complete responses and 11 partial responses. Responses occurred in 28% of patients with disease within the radiation field only and in 57% of patients with disease involving other sites. The median duration of response was 5.5 months, and the median times to progression and survival for all patients were 5 and 9 months, respectively. Grade 3 or 4 toxicities included anemia in 18% of patients and granulocytopenia in 15% of patients. Fifty-three percent of patients developed some degree of neurotoxicity; 21% of cases were grade 2 or worse. CONCLUSION: The combination of paclitaxel with cisplatin seems relatively well tolerated and moderately active in patients with metastatic or recurrent cervical cancer. The significant incidence of neurotoxicity is of concern, and alternative methods of administration of the two agents could be evaluated. Then, further study of this combination, alone or with the addition of other active agents, is warranted.  (+info)

(2/646) Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

(3/646) Longevity, stress response, and cancer in aging telomerase-deficient mice.

Telomere maintenance is thought to play a role in signaling cellular senescence; however, a link with organismal aging processes has not been established. The telomerase null mouse provides an opportunity to understand the effects associated with critical telomere shortening at the organismal level. We studied a variety of physiological processes in an aging cohort of mTR-/- mice. Loss of telomere function did not elicit a full spectrum of classical pathophysiological symptoms of aging. However, age-dependent telomere shortening and accompanying genetic instability were associated with shortened life span as well as a reduced capacity to respond to stresses such as wound healing and hematopoietic ablation. In addition, we found an increased incidence of spontaneous malignancies. These findings demonstrate a critical role for telomere length in the overall fitness, reserve, and well being of the aging organism.  (+info)

(4/646) Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.

Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =.01) and hemorrhagic cystitis (32% v 10%, P =.003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P =.05). Death from GVHD was more common in the busulfan group (22% v 3%, P <.001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P <.01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P <.001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P =.02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P =.004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P <.01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively.  (+info)

(5/646) Clomipramine-induced urinary retention in a cat.

A 10-year-old, female, spayed shorthair with presumed psychogenic alopecia was treated with clomipramine (1 mg/kg body weight/day). The cat developed urinary retention within 2 days. Clomipramine was discontinued. Clinical signs resolved over the next 7 days. The urinary retention was attributed to the anticholinergic effects of clomipramine.  (+info)

(6/646) Identification of a genetic defect in the hairless gene in atrichia with papular lesions: evidence for phenotypic heterogeneity among inherited atrichias.

Recently, we showed that atrichia with papular lesions (APL), a rare inherited form of alopecia, is transmitted as an autosomal recessive trait in a large inbred kindred of Israeli-Arab origin. Furthermore, we mapped the APL locus to a 5-cM region of chromosome 8p12 in this family. The human "hairless" gene is a candidate target gene for the disease mutation because it maps to the APL locus and because it was recently found to be mutated in a related but clinically distinct form of alopecia known as "alopecia universalis" or "congenital alopecia." In the present study, the coding sequence of the hairless gene was compared by reverse transcription-PCR in fibroblast cell lines derived from an affected patient and an unrelated individual. We identified a single-base deletion (3434delC) in the hairless gene that cosegregated with the disease phenotype in the family. This deletion is predicted to cause a frameshift mutation in the highly conserved C-terminal part of the hairless protein, a region putatively involved in the transcription factor activity of the hairless gene product. The present results are indicative of phenotypic heterogeneity in inherited atrichias caused by mutations in the hairless gene, suggesting different roles for the regions mutated in APL and in other forms of congenital atrichia during hair development.  (+info)

(7/646) Medical treatments for balding in men.

Two drugs are available for the treatment of balding in men. Minoxidil, a topical product, is available without a prescription in two strengths. Finasteride is a prescription drug taken orally once daily. Both agents are modestly effective in maintaining (and sometimes regrowing) hair that is lost as a result of androgenic alopecia. The vertex of the scalp is the area that is most likely to respond to treatment, with little or no hair regrowth occurring on the anterior scalp or at the hairline. Side effects of these medications are minimal, making them suitable treatments for this benign but psychologically disruptive condition.  (+info)

(8/646) Insulin gene polymorphism and premature male pattern baldness in the general population.

Insulin is found in hair follicles and may play a role in the regulation of androgen metabolism and the hair growth cycle, which are relevant to the loss of scalp hair known as male pattern baldness. An excess of dihydrotestosterone on balding scalp indicates that the condition is androgen dependent. Premature male pattern baldness may be the male phenotype of familial polycystic ovary syndrome, a condition characterized by high levels of androgens and insulin that has been linked to insulin gene polymorphism. Therefore, we studied possible associations between relevant insulin gene polymorphisms and premature male pattern baldness in the general community. We examined the distribution of three dimorphic restriction fragment length polymorphisms: HphI, PstI and FokI in cases consisting of 56 men aged 18-30 years with significant baldness, and in 107 control men aged 50 years or more with no indication of baldness. No significant differences between cases and controls in allele, genotype or haplotype frequencies were identified. We conclude that, in the general population, the insulin gene is not associated with premature male pattern baldness.  (+info)

Notice: A non well formed numeric value encountered in /home/lookformedical/www/faq.php on line 57
  • frontal fibrosin
  • Even though this "fringe sign" is considered a useful clinical marker of this condition, cases of frontal fibrosing alopecia presenting with an unusual retention of the hairline (pseudo-fringe sign) have been described. (
  • Frontal Fibrosing Alopecia is the frontotemporal hairline recession and eyebrow loss in postmenopausal women that is associated with perifollicular erythema, especially along the hairline. (
  • Frontal Fibrosing Alopecia has been most often reported in post-menopausal women with higher levels of affluence and a negative smoking history. (
  • Although the pathogenesis of Frontal Fibrosing Alopecia is poorly understood, autoimmune reaction and hormonal factors may play a role. (
  • In one study, the use of anti-androgens (finasteride or dutasteride) was associated with improvement in 47% and stabilization in 53% of patients Recently, successful treatment of facial papules in patients with frontal fibrosing alopecia was described with oral isotretinoin. (
  • Macdonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 cases. (
  • Banka N, Mubki T, Bunagan MJ, Mcelwee K, Shapiro J. Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up. (
  • Pirmez R, Donati A, Valente NS, Sodré CT, Tosti A. Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement. (
  • Depression of the frontal veins: A new clinical sign of frontal fibrosing alopecia. (
  • Pirmez R, Duque-Estrada B, Donati A, Campos-do-Carmo G, Valente NS, Romiti R, Sodré CT, Tosti A. Clinical and dermoscopic features of lichen planus pigmentosus in 37 patients with frontal fibrosing alopecia. (
  • Frontal fibrosing alopecia: a multicenter review of 355 patients. (
  • Pirmez R, Duque-Estrada B, Barreto T, Quintella DC, Cuzzi T. Successful Treatment of Facial Papules in Frontal Fibrosing Alopecia with Oral Isotretinoin. (
  • typically
  • Ferret adrenal disease is extremely common and is the most common cause of alopecia in ferrets, typically affecting middle-aged specimens between three and seven years old. (
  • susceptible
  • It was only recently after ongoing episodic thrush outbreaks and further study have I read that due to my immune disorder (alopecia) that I am more susceptible to thrush outbreaks. (
  • genetic
  • Strong evidence of genetic association with increased risk for alopecia areata was found by studying families with two or more affected members. (
  • In addition, alopecia areata shares genetic risk factors with other autoimmune diseases, including rheumatoid arthritis , type 1 diabetes , and celiac disease . (
  • Genetic factors may contribute to AU as approximately 20% of those affected have a family member with alopecia. (
  • cats
  • Dermatophytosis as a cause of alopecia is common in cats, too, and in long-haired varieties, dermatophytic pseudomycetomas may be to blame. (
  • common
  • Canine pinnal alopecia is most common in dachshunds, but others, such as Chihuahuas, Boston terriers, whippets and Italian greyhounds, may also be vulnerable. (
  • cases
  • In cases of alopecia areata, hair will tend to pull out more easily along the edge of the patch where the follicles are already being attacked by the body's immune system than away from the patch where they are still healthy. (